It seems that monitoring of iron and its related metabolites such as ferritin levels and transferrin saturation in serum of patients with metabolic syndrome, MAFLD (metabolic associated fat liver disease), cardiovascular disorders, NASH (nonalcoholic steatohepatitis) and so on is imperative, particularly in MAFLD and NASH, because iron deposition may lead to toxicity-mediated liver failure. This evidence concerns the gene TF and metabolic dysfunction-associated steatohepatitis.